Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075439 · ClinicalTrials.gov registry record · Phase 2
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00075439: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00075439 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00075439, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
Interventions
- OTHER laboratory biomarker analysis
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075439
The ClinicalTrials.gov registry entry for NCT00075439 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00075439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075439 about?
NCT00075439 is a clinical study titled "Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors". This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
What is the current status of trial NCT00075439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2003-12.
What interventions are being tested in trial NCT00075439?
The interventions under investigation include: laboratory biomarker analysis (OTHER), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00075439?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.